BACKGROUND:Beta(2)-adrenergic receptor (beta2-AR) is a susceptibility locus for hypertension, and polymorphisms at this site relate to salt sensitivity and low plasma renin activity (PRA). The Dietary Approaches to Stop Hypertension (DASH) dietary pattern lowers blood pressure and appears to interact with the renin-angiotensin-aldosterone system (RAAS). OBJECTIVE: We hypothesized that the DASH diet associates with increased RAAS activity, and genotype status at beta2-AR G46A modifies this response. DESIGN: We genotyped participants in the DASH-Sodium study (n = 372) at beta2-AR G46A to determine the association with blood pressure, RAAS components, and consumption of the DASH diet. We used 2-way mixed linear regression and an additive model for all primary analyses. RESULTS:Mean (+/-SEM) PRA was significantly higher in participants in the DASH group than in participants in the control group (0.68 +/- 0.03 compared with 0.54 +/- 0.03 ng x mL(-1) x h(-1), P = 0.002). Serum aldosterone, urinary aldosterone, and urinary potassium concentrations were also significantly higher in the DASH group (P < 0.01 for all). We observed significant gene-diet interactions for changes in systolic blood pressure (SBP) and concentrations of aldosterone and urinary potassium (P for interaction = 0.048, 0.017, and 0.001 for SBP and aldosterone and urinary potassium concentrations, respectively). There was an association between the A allele of beta2-AR G46A and greater blood pressure reduction and blunted aldosterone and PRA responses to the DASH diet. CONCLUSIONS: Our results indicate that the DASH diet lowers blood pressure and increases PRA and aldosterone concentrations. There is an association between the G46A polymorphism of beta2-AR and blood pressure and RAAS responses to the DASH diet, which suggests that beta2-AR may be a genetic modifier of DASH-diet responsiveness. This trial was registered at clinicaltrials.gov as NCT00000608.
RCT Entities:
BACKGROUND:Beta(2)-adrenergic receptor (beta2-AR) is a susceptibility locus for hypertension, and polymorphisms at this site relate to salt sensitivity and low plasma renin activity (PRA). The Dietary Approaches to Stop Hypertension (DASH) dietary pattern lowers blood pressure and appears to interact with the renin-angiotensin-aldosterone system (RAAS). OBJECTIVE: We hypothesized that the DASH diet associates with increased RAAS activity, and genotype status at beta2-ARG46A modifies this response. DESIGN: We genotyped participants in the DASH-Sodium study (n = 372) at beta2-ARG46A to determine the association with blood pressure, RAAS components, and consumption of the DASH diet. We used 2-way mixed linear regression and an additive model for all primary analyses. RESULTS: Mean (+/-SEM) PRA was significantly higher in participants in the DASH group than in participants in the control group (0.68 +/- 0.03 compared with 0.54 +/- 0.03 ng x mL(-1) x h(-1), P = 0.002). Serum aldosterone, urinary aldosterone, and urinary potassium concentrations were also significantly higher in the DASH group (P < 0.01 for all). We observed significant gene-diet interactions for changes in systolic blood pressure (SBP) and concentrations of aldosterone and urinary potassium (P for interaction = 0.048, 0.017, and 0.001 for SBP and aldosterone and urinary potassium concentrations, respectively). There was an association between the A allele of beta2-ARG46A and greater blood pressure reduction and blunted aldosterone and PRA responses to the DASH diet. CONCLUSIONS: Our results indicate that the DASH diet lowers blood pressure and increases PRA and aldosterone concentrations. There is an association between the G46A polymorphism of beta2-AR and blood pressure and RAAS responses to the DASH diet, which suggests that beta2-AR may be a genetic modifier of DASH-diet responsiveness. This trial was registered at clinicaltrials.gov as NCT00000608.
Authors: Maciej Tomaszewski; Nick J R Brain; Fadi J Charchar; William Y S Wang; Beata Lacka; Sandosh Padmanabahn; James S Clark; Niall H Anderson; Helen V Edwards; Ewa Zukowska-Szczechowska; Wladyslaw Grzeszczak; Anna F Dominiczak Journal: Hypertension Date: 2002-09 Impact factor: 10.190
Authors: F M Sacks; L P Svetkey; W M Vollmer; L J Appel; G A Bray; D Harsha; E Obarzanek; P R Conlin; E R Miller; D G Simons-Morton; N Karanja; P H Lin Journal: N Engl J Med Date: 2001-01-04 Impact factor: 91.245
Authors: L P Svetkey; T J Moore; D G Simons-Morton; L J Appel; G A Bray; F M Sacks; J D Ard; R M Mortensen; S R Mitchell; P R Conlin; M Kesari Journal: J Hypertens Date: 2001-11 Impact factor: 4.844
Authors: M S Bray; J Krushkal; L Li; R Ferrell; S Kardia; C F Sing; S T Turner; E Boerwinkle Journal: Circulation Date: 2000-06-27 Impact factor: 29.690
Authors: Paul R Conlin; Thomas P Erlinger; Arline Bohannon; Edgar R Miller; Lawrence J Appel; Laura P Svetkey; Thomas J Moore Journal: Am J Hypertens Date: 2003-05 Impact factor: 2.689
Authors: Denise G Simons-Morton; Jeffrey C Chan; Angela R Kimel; Peter E Linz; Cynthia L Stowe; John Summerson; Walter T Ambrosius Journal: Contemp Clin Trials Date: 2013-12-17 Impact factor: 2.226
Authors: Laura P Svetkey; Emily L Harris; Eden Martin; William M Vollmer; Gayle T Meltesen; Vincent Ricchiuti; Gordon Williams; Lawrence J Appel; George A Bray; Thomas J Moore; Michelle P Winn; Paul R Conlin Journal: Am J Hypertens Date: 2010-11-18 Impact factor: 2.689
Authors: Tina Gupta; Molly Connors; Jia Wei Tan; Worapaka Manosroi; Noha Ahmed; Pei Yee Ting; Amanda E Garza; Jose R Romero; Paul N Hopkins; Jonathan S Williams; Gordon H Williams Journal: Am J Hypertens Date: 2017-12-08 Impact factor: 2.689